Barclays
EWTX icon

Barclays’s Edgewise Therapeutics EWTX Stock Holding History

Barclays’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.73M Buy
190,205
+12,961
+7% +$447K ﹤0.01% 1615
2026
Q1 		$5.58M Sell
177,244
-195,494
-52% -$5.64M ﹤0.01% 1753
2025
Q4 		$9.25M Buy
372,738
+138,088
+59% +$2.77M ﹤0.01% 1734
2025
Q3 		$3.81M Sell
234,650
-46,600
-17% -$661K ﹤0.01% 2403
2025
Q2 		$3.69M Buy
281,250
+172,688
+159% +$2.49M ﹤0.01% 2361
2025
Q1 		$2.39M Sell
108,562
-25,095
-19% -$658K ﹤0.01% 2496
2024
Q4 		$3.57M Buy
133,657
+14,307
+12% +$456K ﹤0.01% 2448
2024
Q3 		$3.19M Buy
119,350
+88,826
+291% +$1.77M ﹤0.01% 2466
2024
Q2 		$550K Sell
30,524
-56,720
-65% -$989K ﹤0.01% 2984
2024
Q1 		$1.59M Sell
87,244
-691,672
-89% -$11M ﹤0.01% 2763
2023
Q4 		$8.52M Buy
778,916
+760,637
+4,161% +$5.34M ﹤0.01% 1634
2023
Q3 		$105K Buy
18,279
+1,003
+6% +$6.82K ﹤0.01% 3586
2023
Q2 		$134K Sell
17,276
-10,740
-38% -$90.6K ﹤0.01% 3436
2023
Q1 		$187K Buy
28,016
+9,783
+54% +$90.7K ﹤0.01% 3828
2022
Q4 		$163K Buy
18,233
+8,918
+96% +$83.6K ﹤0.01% 3961
2022
Q3 		$91K Sell
9,315
-209,993
-96% -$2.12M ﹤0.01% 3570
2022
Q2 		$1.75M Sell
219,308
-652
-0.3% -$4.93K ﹤0.01% 1952
2022
Q1 		$2.13M Buy
+219,960
New +$2.83M ﹤0.01% 1808

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays's EWTX Position: Q2 2026 in Review

Barclays increased its Edgewise Therapeutics (EWTX) stake by 7.3% in Q2 2026, buying an estimated $447K and bringing the position to 190,205 shares worth $7.73M. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

Barclays first reported a position in EWTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $9.25M in Q4 2025. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Barclays held 190,205 shares of Edgewise Therapeutics worth $7.73M as of Q2 2026.
  • Barclays bought 12,961 Edgewise Therapeutics shares in Q2 2026, an estimated $447K.
  • Edgewise Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1615 holding.
  • Barclays first reported a position in Edgewise Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Edgewise Therapeutics position peaked at $9.25M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.